Drug Search by Year (Detail)

26915243

RU

Disease progression,

RITUXIMAB, CHLORAMBUCIL, CHLORAMBUCIL, BENDAMUSTINE HCL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, METHOTREXATE, METHOTREXATE SODIUM,

26915645

EU

Disease progression, Haematopoietic stem cell mobilisation, Hodgkin^s disease refractory, Nephropathy toxic, White blood cell count abnormal, C-reactive protein abnormal, Blood lactate dehydrogenase abnormal, Platelet count abnormal, Haemoglobin abnormal, Pyrexia, Night sweats, Product use issue,

DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, DOXORUBICIN, VINCRISTINE SULFATE, VINCRISTINE SULFATE, PREDNISONE, PREDNISONE, CISPLATIN, CYTARABINE, CYTARABINE, OXALIPLATIN, VINORELBINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LORATADINE, LORATADINE ORAL, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, BRENTUXIMAB VEDOTIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PEMBROLIZUMAB, BRENTUXIMAB VEDOTIN, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, VINORELBINE, PREDNISONE,

26915745

JP

Death, Disease progression, Hypoxia,

26916638

US

Breast mass, Disease progression, Atrial fibrillation, Diabetes mellitus, Hypertension, Diarrhoea, Dehydration,

SACITUZUMAB GOVITECAN, TUCATINIB, CAPIVASERTIB, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG,

26916879

IN

Disease progression, Off label use, Cholangitis acute, Bile duct stone,

ATEZOLIZUMAB,

26917552

US

Neutropenia, Disease progression, Thrombocytopenia, Aspergillus infection, Central nervous system lesion, Drug resistance,

ISAVUCONAZONIUM SULFATE, VORICONAZOLE, VORICONAZOLE INJECTION, AMPHOTERICIN B, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, SIROLIMUS,

26917644

US

Drug ineffective, Disease progression,

DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOCETAXEL, DOCETAXEL ANHYDROUS, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB, PERTUZUMAB, PERTUZUMAB, PERTUZUMAB, PERTUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION,

26918083

CA

Fatigue, Depressed mood, Disease progression,

RIBOCICLIB, RIBOCICLIB, ANASTROZOLE, ANASTROZOLE TABLETS,

26918581

US

Eczema, Hidradenitis, Disease progression,

SECUKINUMAB,

26918826

Disease progression,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26918828

Disease progression,

DATOPOTAMAB DERUXTECAN,

26918830

Disease progression,

DATOPOTAMAB DERUXTECAN,

26919012

JP

Disease progression,

TAZEMETOSTAT,

26919275

Disease progression, Drug ineffective,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26919463

EU

Disease progression, Drug ineffective, Febrile neutropenia, Mucosal inflammation, Dyspnoea,

DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, BRENTUXIMAB VEDOTIN, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, ETOPOSIDE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR, GANCICLOVIR SODIUM, GANCICLOVIR,

26909533

MX

Disease progression,

ATEZOLIZUMAB,

26909581

JP

Cytokine release syndrome, Disease progression,

MOSUNETUZUMAB, POLATUZUMAB VEDOTIN,

26910055

EU

Disease progression, Splenectomy, Off label use,

DARATUMUMAB,

26910410

PK

Hyperpyrexia, Decreased appetite, Disease progression, Asthenia,

ATEZOLIZUMAB, BEVACIZUMAB,

26910657

US

Myasthenic syndrome, Disease progression, Neuropathy peripheral, Joint swelling, Drug hypersensitivity,

AMIFAMPRIDINE PHOSPHATE, AMIFAMPRIDINE PHOSPHATE, LISINOPRIL, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, HYDROCHLOROTHIAZIDE,

26910978

US

Thrombocytopenia, Disease progression, Neutropenia, Aspergillus infection, Central nervous system lesion, Drug resistance,

AMPHOTERICIN B, VORICONAZOLE, VORICONAZOLE INJECTION, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, SIROLIMUS,

26911015

EU

Disease progression,

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN,

26911091

Condition aggravated, Disease progression, Off label use,

PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION,

26911180

EU

Disease progression, Rash, Cardiac failure,

LENALIDOMIDE, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, MELPHALAN HYDROCHLORIDE, MELPHALAN, CARFILZOMIB, DARATUMUMAB, DARATUMUMAB,

26911192

EU

Metabolic acidosis, Infection, Disease progression, Polyneuropathy, Therapeutic product effect incomplete,

DOXORUBICIN, THALIDOMIDE, THALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, BORTEZOMIB, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, POMALIDOMIDE, DARATUMUMAB, DARATUMUMAB, BENDAMUSTINE HCL, ELOTUZUMAB, CARFILZOMIB, ISATUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION,

26911193

CN

Disease progression,

CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND),

26911495

KR

Disease progression, Drug ineffective,

GEMCITABINE HYDROCHLORIDE, GEMCITABINE, DOXORUBICIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CISPLATIN, PREDNISONE, RITUXIMAB, ETOPOSIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION,

26911694

EU

Disease progression, Necrosis, Off label use,

MELPHALAN HYDROCHLORIDE, MELPHALAN, BUSULFAN,

26911930

US

Disease progression,

SOTORASIB,

26912093

EU

Blast crisis in myelogenous leukaemia, Treatment failure, Drug ineffective, Disease progression, Anaemia,

IMATINIB, DASATINIB, ASCIMINIB, BOSUTINIB,

26912101

CA

Terminal state, Nausea, Decreased appetite, Cough, Malaise, Diarrhoea, Diverticulitis, Influenza, Alopecia, Disease progression, Dyspnoea exertional, Weight gain poor, Taste disorder, Fatigue, Hypersomnia, Oxygen saturation abnormal,

NINTEDANIB, NINTEDANIB,

26912224

RU

Asthenia, Disease progression, Skin lesion,

TRASTUZUMAB, PERTUZUMAB,

26912320

US

Disease progression, Off label use,

TOVORAFENIB,

26912612

EU

Disease progression, Therapeutic product effect incomplete,

OFATUMUMAB,

26912915

US

Drug ineffective, Disease progression,

LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE,

26913277

Disease progression, Corneal epitheliopathy, Stomatitis,

DATOPOTAMAB DERUXTECAN, DATOPOTAMAB DERUXTECAN,

26913278

Disease progression,

DATOPOTAMAB DERUXTECAN,

26913280

Disease progression,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26913282

Disease progression, Nausea,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26913380

EU

Influenza, Basal cell carcinoma, COVID-19, Disease progression, Obstructive sleep apnoea syndrome, Osteoarthritis, Device related infection, Rhinitis, Road traffic accident, Prostatic specific antigen increased, Inguinal hernia,

NINTEDANIB, NINTEDANIB, OXYGEN, 0XYGEN, TERBINAFINE HYDROCHLORIDE, TERBINAFINE, TERBINAFINE HYDROCHLORIDE TABLET, FLUCONAZOLE, PREDNISONE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, FENTANYL, AZELASTINE HYDROCHLORIDE, AZELASTINE, AZELASTINE HYDROCHLORIDE, AZELASTINE, LORAZEPAM, PANTOPRAZOLE,

26913500

Disease progression,

BELZUTIFAN,

26913707

Disease progression, Metastases to soft tissue,

FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI, FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26913825

EU

Toxic epidermal necrolysis, Drug reaction with eosinophilia and systemic symptoms, Hypertransaminasaemia, Renal failure, Ascites, Systemic inflammatory response syndrome, Pseudomonas infection, COVID-19, Skin ulcer, Hypotension, General physical health deterioration, Cytomegalovirus infection, Disease progression, Oedema, Staphylococcal infection, Fluid intake reduced,

RITUXIMAB, MEROPENEM, CEFTAROLINE FOSAMIL, ACYCLOVIR, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, DOXORUBICIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, LENALIDOMIDE, ALBUMIN HUMAN, ALLOPURINOL, FOLIC ACID, SODIUM BICARBONATE, SODIUM BICARBONATE, INJECTION, SODIUM BICARBONATE INJECTION,, CALCIUM CHLORIDE INJECTION, CALCIUM CHLORIDE, POTASSIUM PHOSPHATE, MONOBASIC, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, FUROSEMIDE, THIAMINE HYDROCHLORIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG,

26913833

EU

Pneumothorax, Metastasis, Pleural effusion, Disease progression,

CEMIPLIMAB-RWLC,

26914264

BR

Disease progression, Weight decreased, Muscle atrophy, Mobility decreased, Dysphagia,

CERLIPONASE ALFA,

26916952

Disease progression,

PANCRELIPASE LIPASE, PANCRELIPASE PROTEASE, PANCRELIPASE AMYLASE, ACYCLOVIR, AMANTADINE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, AZELASTINE, BRIMONIDINE, BRIMONIDINE TARTRATE, AZTREONAM, DOXYCYCLINE, DOXYCYCLINE HYCLATE, ECONAZOLE NITRATE,

26904706

CN

Product use in unapproved indication, Disease progression, Glomerulonephritis minimal lesion,

TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, METHYLPREDNISOLONE, METHYLPREDNISOLONE,

26904765

CN

Product ineffective for unapproved use, Drug effective for unapproved indication, Disease progression, Glomerulonephritis minimal lesion,

TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, CYCLOSPORINE, PREDNISONE, PREDNISONE, OBINUTUZUMAB, OBINUTUZUMAB,

26904825

US

Ovarian cancer stage IV, Disease progression, Drug dependence, Drug intolerance,

OLAPARIB,

26905112

BR

Disease progression, Cough, Product dose omission issue, Product leakage,

TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO,

26905328

CA

Arthralgia, Back pain, Blood creatinine increased, Bursitis, Deafness, Disease progression, Disease recurrence, Drug intolerance, Dry mouth, Electric shock sensation, Feeling abnormal, Gait disturbance, Glomerular filtration rate decreased, Headache, Hypersensitivity, Hypoaesthesia, Inflammation, Inflammatory marker increased, Joint swelling, Limb discomfort, Movement disorder, Musculoskeletal discomfort, Musculoskeletal stiffness, Neck pain, Nerve compression, Pain, Pain in extremity, Pain in jaw, Paraesthesia, Polyarthritis, Tinnitus, Tachycardia,

DICLOFENAC, DICLOFENAC SODIUM, LOSARTAN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, TOFACITINIB, LEFLUNOMIDE, DICLOFENAC SODIUM, DICLOFENAC SODIUM TOPICAL, DICLOFENAC SODIUM TOPICAL GEL, 1%, DICLOFENAC, DICLOFENAC SODIUM 1%, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ROSUVASTATIN, TRIAMTERENE CAPSULES, TRIAMTERENE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN,

26905395

EU

Disease progression,

POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE,

26905641

JP

Disease progression,

TISLELIZUMAB-JSGR, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL,

26905675

EU

Disease progression,

LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN,

26905931

KR

Septic shock, Multiple organ dysfunction syndrome, Pyrexia, Rash, Hepatitis E, Hepatic failure, Disease progression, Disease progression, Pyrexia, Cytomegalovirus test positive, Dysuria, Somnolence, Vomiting, Stupor, Abdominal distension,

PEGFILGRASTIM,

26905985

JP

Adrenal haemorrhage, Adrenalitis, Shock, Adrenal insufficiency, Disease progression, Cytomegalovirus infection reactivation, Drug ineffective,

HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, NOREPINEPHRINE (BITARTRATE), NOREPINEPHRINE, NOREPINEPHRINE BITARTRATE,

26906080

EU

Disease progression,

VENETOCLAX,

26906163

JP

Disease progression,

AXICABTAGENE CILOLEUCEL,

26906406

EU

Disease progression,

VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, ALLOPURINOL, ACYCLOVIR, FILGRASTIM, RAMIPRIL,

26906850

RU

Disease progression,

OBINUTUZUMAB, BENDAMUSTINE HCL,

26906994

EU

Disease progression, Hodgkin^s disease, Haematopoietic stem cell mobilisation, Hodgkin^s disease refractory, Haematopoietic stem cell mobilisation, Nephropathy toxic, Disease progression, White blood cell count abnormal, C-reactive protein abnormal, Blood lactate dehydrogenase abnormal, Platelet count abnormal, Haemoglobin abnormal, Pyrexia, Night sweats, Disease progression, Drug ineffective, Product use issue, Product use issue, Product use issue,

RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ETOPOSIDE, ETOPOSIDE, DOXORUBICIN, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CYTARABINE, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN, LORATADINE, LORATADINE ORAL, GENTAMICIN, GENTAMICIN SULFATE, CYTARABINE, CYTARABINE, ETOPOSIDE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, PREDNISONE, BRENTUXIMAB VEDOTIN, PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, VINORELBINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, BRENTUXIMAB VEDOTIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, VINCRISTINE SULFATE, VINCRISTINE SULFATE, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, VINORELBINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, VINORELBINE,

26907315

US

Product ineffective for unapproved use, Disease progression, Pneumonitis, Condition aggravated, Drug intolerance, Product prescribing issue,

OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, OXALIPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), MESNA, MESNA INJECTION, MESNA, MESNA INJECTION, MESNA, MESNA INJECTION, MESNA, MESNA INJECTION, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, NIVOLUMAB, RAMUCIRUMAB, RAMUCIRUMAB, RAMUCIRUMAB, RAMUCIRUMAB, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, IFOSFAMIDE, IFOSFAMIDE FOR INJECTION, CISPLATIN, CISPLATIN, CISPLATIN, CISPLATIN,

26907316

EU

Polyneuropathy, Disease progression, Drug ineffective, Product prescribing issue,

DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, DOXORUBICIN, BENDAMUSTINE HCL, BENDAMUSTINE HCL, BENDAMUSTINE HCL, BENDAMUSTINE HCL, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, POMALIDOMIDE, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, BORTEZOMIB, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, THALIDOMIDE, ISATUXIMAB, ISATUXIMAB, ISATUXIMAB, ISATUXIMAB, DARATUMUMAB, DARATUMUMAB, DARATUMUMAB, DARATUMUMAB, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, ELOTUZUMAB, ELOTUZUMAB, ELOTUZUMAB, ELOTUZUMAB, CARFILZOMIB, CARFILZOMIB, CARFILZOMIB, CARFILZOMIB,

26907490

KR

Disease progression,

SACITUZUMAB GOVITECAN,

26907499

GB

Disease progression,

SACITUZUMAB GOVITECAN,

26907747

Disease progression,

DATOPOTAMAB DERUXTECAN,

26907749

Disease progression, Nausea, Malaise, Oral discomfort, Nausea, Stomatitis, Off label use, Product dose omission issue, Inappropriate schedule of product administration,

DATOPOTAMAB DERUXTECAN,

26907751

Disease progression,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26907769

US

Brain neoplasm malignant, Disease progression,

OXALIPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, BEVACIZUMAB, ENCORAFENIB,

26907903

EU

Cardiac arrest, Oxygen saturation decreased, Disease progression, Necrosis, Staphylococcal infection, Dyspnoea exertional, Oxygen saturation decreased, Fibrosis,

NINTEDANIB,

26908158

Disease progression, Off label use,

DATOPOTAMAB DERUXTECAN,

26908159

Disease progression, Nausea,

DATOPOTAMAB DERUXTECAN,

26908425

EU

Disseminated aspergillosis, Disease progression, Therapeutic product effect incomplete,

AMPHOTERICIN B, ACYCLOVIR, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION,

26908649

EU

Disease progression, Metastases to spine, Nerve compression, Paraparesis,

ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE, ABIRATERONE ACETATE, ABIRATERONE,

26908955

Disease progression, Metastases to liver, Metastases to kidney, Haematotoxicity, Nausea, Vomiting,

FAM-TRASTUZUMAB DERUXTECAN-NXKI,

26908964

Death, Disease progression,

DATOPOTAMAB DERUXTECAN,

26909007

EU

Hepatotoxicity, Dry eye, Drug ineffective, Skin lesion, Dry mouth, Leukoplakia, Lymphocytic infiltration, Dysphagia, Chronic graft versus host disease, Muscle atrophy, Acute graft versus host disease, Chronic graft versus host disease in skin, Hypercreatinaemia, Disease progression,

IMATINIB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOSPORINE, RUXOLITINIB, METHOTREXATE, METHOTREXATE SODIUM,

26912738

Diarrhoea, Cardiac ventricular thrombosis, Aortic aneurysm, Disease progression, Fatigue, Asthenia, Syncope,

TRASTUZUMAB,

26904096

EU

Respiratory failure, Interstitial lung disease, Lung opacity, Rales, Pulmonary embolism, Pulmonary toxicity, Lymphocytosis, Interstitial lung abnormality, Disease progression, Bronchiectasis, Pneumonia,

CABAZITAXEL, DOCETAXEL, DOCETAXEL ANHYDROUS, OLAPARIB, ABIRATERONE ACETATE, ABIRATERONE,

26904126

Treatment noncompliance, Disease progression, Pain, Skin lesion,

DEXAMETHASONE, DEXAMETHASONE 1.5 MG, BORTEZOMIB, LENALIDOMIDE, DARATUMUMAB, ISATUXIMAB, CARFILZOMIB,

26904351

BR

Disease progression,

TISLELIZUMAB-JSGR, TISLELIZUMAB-JSGR,

26903389

KR

Septic shock, Oral herpes, Disease recurrence, Disease progression, Asthenia, Pain of skin,

PEGFILGRASTIM,

26897746

EU

Disease progression,

NERANDOMILAST, PIRFENIDONE, OXYGEN, 0XYGEN, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, PANTOPRAZOLE,

26897772

EU

Disease progression,

VENETOCLAX,

26897843

PK

Disease progression,

TRASTUZUMAB,

26898570

EU

Disease progression,

VENETOCLAX,

26898633

EU

Adenocarcinoma, Disease progression,

ENZALUTAMIDE, DOCETAXEL, DOCETAXEL ANHYDROUS, OLAPARIB, CABAZITAXEL,

26898924

US

Metastases to central nervous system, Disease progression, Drug ineffective, Neuropathy peripheral,

GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), FLUOROURACIL CREAM, 0.5%, FLUOROURACIL,

26898967

EU

Disease progression, Myocardial infarction,

VENETOCLAX,

26899192

Acute kidney injury, C-reactive protein increased, Cardiac failure, Confusional state, Congestive hepatopathy, Disease progression, Fall, Hydrocele, Hypokalaemia, Hypovolaemia, Orthostatic hypotension, Respiratory distress, Skin lesion,

FUROSEMIDE, FUROSEMIDE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, BISOPROLOL FUMARATE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, PREGABALIN, PREGABALIN, PREGABALIN, RISEDRONATE SODIUM, RISEDRONATE SODIUM, SPIRONOLACTONE, SPIRONOLACTONE, SPIRONOLACTONE, SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, SACUBITRIL AND VALSARTAN, SPIRONOLACTONE, SPIRONOLACTONE, DULOXETINE HYDROCHLORIDE, DULOXETINE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, DEXLANSOPRAZOLE, DEXLANSOPRAZOLE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, FERROUS SULFATE, FERROUS SULFATE, HYDROCHLOROTHIAZIDE, MIRABEGRON, MIRABEGRON, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, PREGABALIN, PREGABALIN, PREGABALIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE, DALTEPARIN SODIUM, MELATONIN, NICOTINE, TOBACCO LEAF, RISPERIDONE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER,

26899454

TR

Disease progression,

IMIQUIMOD,

26899466

JP

Neuropathy peripheral, Disease progression,

OXALIPLATIN, LEUCOVORIN CALCIUM, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL,

26899556

EU

Disease progression, Hypogammaglobulinaemia, Drug ineffective,

RITUXIMAB, MOSUNETUZUMAB, OBINUTUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, PREDNISONE, BENDAMUSTINE HCL, ZANUBRUTINIB,

26899741

EU

Metastases to liver, Metastases to bone, Metastases to pleura, Disease progression, Abdominal discomfort, Lymphadenopathy,

CAPECITABINE, FULVESTRANT, OLAPARIB, ABEMACICLIB, DENOSUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND),

26900166

EU

Disease progression, Hypertrophic cardiomyopathy, Hyperuricaemia,

PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION,

26900327

Disease progression,

DATOPOTAMAB DERUXTECAN,

26900593

EU

Disease progression, Balance disorder, Acute myocardial infarction,

ATEZOLIZUMAB,

26900986

EU

Disease progression,

OXALIPLATIN, CAPECITABINE,

26900988

KR

Diffuse large B-cell lymphoma recurrent, Disease progression,

GEMCITABINE HYDROCHLORIDE, GEMCITABINE, CARBOPLATIN, DOXORUBICIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, PREDNISONE, RITUXIMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, POLATUZUMAB VEDOTIN,

26901019

EU

Lymphoma, Disease progression, Gait disturbance, Dysstasia,

VUTRISIRAN,